Tirzepatide

Yes — a genuinely effective, approved medicine with the largest weight-loss effect of any approved obesity drug so far. Like semaglutide, the compounded/grey-market version is not the same legal thing as the branded pen; FDA's 503B proposal on it is not final.

Evidence grade A: what kinds of studies support the claims on this page, with limits. It is not a verdict on any product. How we grade

What it is

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist — a once-weekly injectable, developed by Eli Lilly.

What the trial evidence shows

SURMOUNT-1 (Jastreboff et al., N Engl J Med 2022, DOI 10.1056/NEJMoa2206038, PMID 35658024) followed 2,539 adults with obesity or overweight, without diabetes, for 72 weeks: mean weight loss ranged 15–20.9% by dose versus 3.1% on placebo — the largest effect size reported for an approved anti-obesity drug at the time. Approved as Mounjaro for type 2 diabetes in May 2022, then as Zepbound for chronic weight management in November 2023. A later trial (Jastreboff et al., N Engl J Med 2024) reported it reduced progression to type 2 diabetes in adults with prediabetes and obesity.

The compounded/grey-market version

Same situation as semaglutide: compounding was permitted during the 2022–2024 shortage (removed from FDA's shortage list on 2 October 2024, then determined resolved again in a declaratory order of 19 December 2024), and FDA's proposal not to include it on the 503B bulks list names tirzepatide alongside semaglutide and liraglutide (announced 30 April 2026; Federal Register, 1 May 2026, document 2026-08552). The notice records that FDA-approved tirzepatide products were not on FDA's drug shortage list at its date; the proposal is not final.

Safety notes

Gastrointestinal effects dominate the side-effect profile, similar to GLP-1-only drugs but sometimes more pronounced given the added GIP agonism. The class carries the same thyroid C-cell tumor boxed warning as semaglutide, based on rodent data, with the same contraindication for a personal or family history of medullary thyroid carcinoma or MEN2.

One safety question specific to this drug, rather than shared with semaglutide: a rare eye condition, NAION (non-arteritic anterior ischemic optic neuropathy), that regulators reviewed across the whole GLP-1/GIP class after a signal first emerged for semaglutide. Australia's TGA Advisory Committee on Medicines concluded in October 2025 that the evidence may support the signal for semaglutide specifically, but not for tirzepatide or dulaglutide. That's a real distinction, not a clean acquittal — the TGA's own adverse-event database still held 10 tirzepatide-linked reports of the condition (against 23 for semaglutide) when its class-wide safety alert was published in July 2026. See semaglutide's own NAION section for the fuller three-regulator picture — the EU and UK reviews so far have concluded specifically on semaglutide, not tirzepatide.

Elsewhere: the same drug, one brand

This page describes tirzepatide's US status, where Eli Lilly filed the obesity indication as a separate new drug application rather than adding it to Mounjaro's existing label — the reason two brand names exist for one molecule. The UK, EU, and Australia all took the opposite approach: each approved the same drug for both type 2 diabetes and chronic weight management under the single Mounjaro brand, with no local equivalent of "Zepbound" at all. The UK's MHRA approved Mounjaro for diabetes in September 2022 and extended it to weight management on 8 November 2023; the EMA followed the same one-brand approach for the EU, authorizing the weight-management indication in April 2024; Australia's TGA approved both indications under Mounjaro via an AusPAR dated September 2024. Same drug, same trials behind it, different branding decisions by four different regulators.

The NHS: rationed by BMI, not by insurance

The UK has no equivalent of a US-style insurance gate on Mounjaro — it has a clinical one, phased in tiers, and it started later than most people assume. NHS England opened GP-level prescribing for weight management ("Cohort 1") on 23 June 2025: adults with a BMI of 40 or higher (37.5 or higher for South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, reflecting a lower risk threshold in those groups) who also have at least 4 of 5 qualifying conditions — type 2 diabetes, hypertension, dyslipidaemia, established cardiovascular disease, or obstructive sleep apnoea. A second tier ("Cohort 2"), effective 23 June 2026, extends eligibility down to a BMI of 35–39.9 (32.5–37.4 ethnicity-adjusted) under the same comorbidity rule. A third tier is planned for April 2027 — not a further BMI reduction, but a loosening of the comorbidity bar for the original BMI-40-plus group, from 4 of 5 conditions down to 3.

Meeting the clinical criteria doesn't guarantee a prescription. Participation requires both the local Integrated Care Board (ICB) to commission and fund the pathway and the individual GP practice to opt in — only 8 of England's 42 ICBs could actually treat patients when Cohort 1 launched, per Sky News's reporting on NHS data; a BMJ investigation published that September found the figure had risen to 18 of 42, and a second BMJ investigation in January 2026 found roughly 1 in 5 areas still lacked a functioning pathway at all. Even where a pathway exists, the national BMI/comorbidity criteria above are a floor rather than a guarantee of identical local rules everywhere: reporting on the Cohort 2/3 rollout found some ICBs layering their own tighter eligibility on top — Lancashire and South Cumbria ICB restricting access to patients in the area's most deprived neighbourhoods, NHS South Yorkshire ICB requiring a documented prior supported weight-loss attempt, and Greater Manchester ICB applying its own local prioritisation within each cohort. A separate change took effect 1 April 2026: tirzepatide prescribing was folded into the 2026/27 GP contract's Quality and Outcomes Framework, adding a financial incentive of up to £3,000 a year per practice and replacing NHS England's prior direct funding of ICB pathways — a funding-mechanism change, not a new eligibility date.

None of this is about cost to the patient in the way US insurance coverage is — an NHS prescription under the eligibility rules above is free at the point of use, same as any other NHS medicine. The rationing is entirely about who qualifies and whether their local area has switched the pathway on, which is why "I meet the criteria" and "I can actually get it through the NHS" are two different questions in the UK right now. Outside the NHS, Mounjaro is also the single most-searched weight-loss drug in the UK — Google Trends data from May 2025 put it roughly 20% ahead of Wegovy — feeding a large private-pharmacy market where list prices rose sharply in September 2025 before Eli Lilly introduced a rebate scheme for participating pharmacies; real-world private pricing is volatile and provider-dependent, roughly £130–£360 a month depending on dose and pharmacy at any given time.

Scotland, Wales and Northern Ireland: one NICE approval, three rollouts

Everything in the section above is NHS England specifically. NICE's technology appraisal (TA1026, published 23 December 2024) — recommending tirzepatide for adults with a BMI of 35 or higher (lower for the ethnic groups noted above) and at least one weight-related comorbidity, available through both primary and secondary care — only binds NHS England. Scotland, Wales and Northern Ireland each run their own separate medicines-approval and rollout processes, and the three have reached three different outcomes.

Scotland moved first, and on paper further: the Scottish Medicines Consortium accepted tirzepatide for NHS Scotland weight management in June 2024 — six months ahead of NICE's own recommendation for England — under a lower BMI threshold (30, versus NICE's 35) plus the same one-comorbidity requirement, with no restriction to specialist clinics built into the SMC's own advice. Turning that into actual appointments has still meant each of Scotland's 14 territorial health boards building its own local pathway and capacity; NHS Lothian, for instance, opened only a small pilot restricted to patients already known to its existing weight-management service rather than a general referral route. Separately, the SMC accepted semaglutide (Wegovy) in June 2026 for a narrower, different purpose — reducing the risk of a further heart attack or stroke in overweight adults who already have cardiovascular disease — not general weight management.

Wales initially pointed the same direction as NICE, confirming in a 2025 health circular (WHC/2025/018) that it would consider extending tirzepatide into GP-level prescribing alongside specialist services. That extension didn't happen. Citing an estimate that around 186,000 people in Wales could qualify under NICE's criteria — more than Welsh Government judged the service could absorb without a slower, staged build-out first — it kept GP prescribing paused and issued a narrower replacement circular in November 2025 (WHC/2025/043) limiting tirzepatide, semaglutide and liraglutide to specialist weight-management services, plus a defined list of higher-need exceptions: people awaiting time-sensitive surgery or an organ transplant, women under a fertility service where weight loss would help conception, and people with conditions such as severe asthma, severe obstructive sleep apnoea or cancer where weight loss would improve access to other treatment. Everyone else in Wales still goes through the same specialist-referral route the NICE appraisal was meant to loosen — and that route's waiting lists have grown sharply since: 2026 reporting found waiting times for weight-management services had doubled at two of Wales's seven health boards and quadrupled at a third, with one board's own published figures showing its list rising from 1,604 people in March 2024 to 3,146 a year later.

Northern Ireland doesn't have a live tirzepatide weight-management pathway at all yet — it's the last of the four UK nations to get one. Its Department of Health announced a new Regional Obesity Management Service on 29 June 2026, with a first phase (£5 million) focused on patients with the highest clinical need due to begin in early autumn 2026, offering weight-loss medication "if clinically appropriate and in line with NICE guidance" once it's actually running. Until that service is seeing patients, a tirzepatide prescription for obesity in Northern Ireland is a private one.

None of this is a coverage denial in the US insurance sense — it's four public health systems making four different calls about capacity and eligibility for the same NICE-recommended drug. But it means "does the NHS cover Mounjaro" doesn't have one UK-wide answer: depending which of the four systems someone is actually in, that can mean an open GP referral, a capacity-limited specialist wait measured in months, or — in parts of Wales specifically — a wait now measured in years.